Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT06756035Phase 1Terminated
- Sponsor
- Context Therapeutics
- Start
- Mar 2025
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT-95 (Context Therapeutics) in solid tumor, sponsored by Context Therapeutics. Primary endpoints: Maximum Tolerated Dose or Recommended Dose at 28 days and Incidence of Treatment-Emergent Adverse Events at 6 months. Started Mar 2025; status: terminated.
02
Drugs
CT-95 (Context Therapeutics)
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06756035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06756035.